1. Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications
   Emma Hays et al, 2017, IJMS CrossRef
2. Epstein–Barr Virus in Gliomas: Cause, Association, or Artifact?
   Saghir Akhtar et al, 2018, Front. Oncol. CrossRef
3. Identification of a Novel Splice Variant of Neural Cell Adhesion Molecule in Glioblastoma Through Proteogenomics Analysis
   Savita Jayaram et al, 2018, OMICS: A Journal of Integrative Biology CrossRef
4. Emerging patents in the therapeutic areas of glioma and glioblastoma
   Matthew Harris et al, 2018, Expert Opinion on Therapeutic Patents CrossRef
5. Salivary exosomes as potential biomarkers in cancer
   Soumyalekshmi Nair et al, 2018, Oral Oncology CrossRef
6. CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis
   J. Randall McAuley et al, 2018, Front. Immunol. CrossRef
7. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes
   Vikas Patil et al, 2018, Gene CrossRef
8. Human Papillomavirus and Human Cytomegalovirus Infection and Association with Prognosis in Patients with Primary Glioblastoma in Pakistan
   Syed Muhammad Adnan Ali et al, 2018, World Neurosurgery CrossRef
9. Genetics of Glioblastoma in Moroccan population: Review of literature
   Hossam Hilal El Idrissi, 2018, IBRO Reports CrossRef
10. Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro
    Yi‐Wen Jiang et al, 2018, Environmental Toxicology CrossRef
11. Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma – Radiogenomic approach for precision medicine
    Kyungmi Yang et al, 2019, Radiotherapy and Oncology CrossRef
12. Pathway-based Deep Clustering for Molecular Subtyping of Cancer
    Tejaswini Mallavarapu et al, 2019, Methods CrossRef
13. Seizures in glioma patients: An overview of incidence, etiology, and therapies
    Niyatee Samudra et al, 2019, Journal of the Neurological Sciences CrossRef
14. An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future
    Muhammad Babar Khawar et al, 2019, Oxidative Medicine and Cellular Longevity CrossRef
15. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
    Samuel J. Reddick et al, 2019, Cancer Chemother Pharmacol CrossRef
16. Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review
    Anahita Fathi Kazerooni et al, 2019, J Magn Reson Imaging CrossRef
17. 3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors
    Disha Sood et al, 2019, Nat Commun CrossRef
18. Identification of Dysregulated Competitive Endogenous RNA Networks Driven by Copy Number Variations in Malignant Gliomas
    Jinyuan Xu et al, 2019, Front. Genet. CrossRef
19. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy
    Ernest Osei et al, 2019, J Radiother Pract CrossRef
20. Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors
    Robert Pola et al, 2020, Pharmaceutics CrossRef
21. Efecto de la alteración de los niveles de expresión de microARN neurogénicos y su implicación en la agresividad de glioblastomas localizados en la región paraventricular
    L.J. Reséndiz-Castillo et al, 2020, Neurología CrossRef
22. The limitations of targeting MEK signalling in Glioblastoma therapy.
    Mike-andrew Westhoff, 0 CrossRef
23. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells
    Nalin Leelatian et al, 2020 CrossRef
24. A compendium of mutational cancer driver genes.
    Francisco Martínez-Jiménez et al, 2020, Nat Rev Cancer CrossRef
25. mTOR Inhibition Leads to Src-Mediated EGFR Internalisation and Degradation in Glioma Cells
    Barbara Colella et al, 2020, Cancers CrossRef
26. Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes
    Ezeddine Harmouch et al, 2020, Sci Rep CrossRef
27. Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab
    Vu Long Tran et al, 2020, Journal of Controlled Release CrossRef
28. Hsa‐miR‐27a‐3p and epidermal growth factor receptor expression analysis in glioblastoma FFPE samples
    Tayyebali Salmani et al, 2020, Asia‐Pac J Clin Oncol CrossRef
29. Inferring tumor progression in large datasets
    Mohammadreza Mohaghegh Neyshabouri et al, 2020, PLoS Comput Biol CrossRef
30. MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations
    Sisheng Liu et al, 2020 CrossRef
31. Differential Network Analysis via Weighted Fused Conditional Gaussian Graphical Model
    Le Ou-Yang et al, 2020, IEEE/ACM Trans. Comput. Biol. and Bioinf. CrossRef
32. Set-Wise Differential Interaction between Copy Number Alterations and Gene Expressions of Lower-Grade Glioma Reveals Prognosis-Associated Pathways
    Seong Beom Cho, 2020, Entropy CrossRef
33. BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis
    Kassandra Koumaki et al, 2021, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
34. Cancer Therapy–Associated Thrombosis
    Steven P. Grover et al, 2021, ATVB CrossRef
35. null
    Shivani Baisiwala et al, 2021 CrossRef
36. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives
    Ana Laura V. Alves et al, 2021, Stem Cell Res Ther CrossRef
37. null
    Hrvoje Vavro, 2021 CrossRef
38. 4-Acetylantrocamol LT3 Inhibits Glioblastoma Cell Growth and Downregulates DNA Repair Enzyme O6-Methylguanine-DNA Methyltransferase
    Shih-Yu Lee et al, 2021, Am. J. Chin. Med. CrossRef
39. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
    Sani H Kizilbash et al, 2021, Mol Cancer Ther CrossRef
40. Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma
    Malik Galijašević et al, 2021, Cancers CrossRef
41. Therapeutic targeting of membrane-associated proteins in central nervous system tumors
    Pritam Kumar Roy et al, 2021, Experimental Cell Research CrossRef
42. Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
    Irene Appolloni et al, 2021, Viruses CrossRef
43. null
    Nuril Muhammad Zidni Amin et al, 2021 CrossRef
44. Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.
    Preantha Poonan et al, 2021, Protein J CrossRef
45. BRAF mutations may identify a clinically distinct subset of glioblastoma
    Samantha N. McNulty et al, 2021, Sci Rep CrossRef
46. Novel Galectin-3 Roles in Neurogenesis, Inflammation and Neurological Diseases
    Luana C. Soares et al, 2021, Cells CrossRef
47. The effects of altered neurogenic microRNA levels and their involvement in the aggressiveness of periventricular glioblastoma
    L.J. Reséndiz-Castillo et al, 2021, Neurología (English Edition) CrossRef
48. The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack
    Abhishek Guha et al, 2021, Advanced Drug Delivery Reviews CrossRef
49. Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors.
    Guanjie Li et al, 2021, Cells CrossRef
50. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
    Kai Chen et al, 2022, Biomedicines CrossRef
51. Investigating Glioblastoma Multiforme Sub-Proteomes: A Computational Study of CUSA Fluid Proteomic Data
    Fabiana Moresi et al, 2022, IJMS CrossRef
52. The p53-Driven Anticancer Effect of Ribes fasciculatum Extract on AGS Gastric Cancer Cells
    Myeong-Jin Kim et al, 2022, Life CrossRef
53. Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma
    Chaeyeong Kim et al, 2022, Toxicol Res. CrossRef
54. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG_2a-f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.
    Ren Nanamiya et al, 2022, Monoclon Antib Immunodiagn Immunother CrossRef
55. Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors
    Mahak Fatima et al, 2022, European Polymer Journal CrossRef
56. Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib
    Scott Owen et al, 2022, OTT CrossRef
57. First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes
    Rahul Pal et al, 2022 CrossRef
58. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions
    Richa Shrivastava et al, 2022, Clin Transl Oncol CrossRef
59. A Historical Review of Brain Drug Delivery
    William M. Pardridge, 2022, Pharmaceutics CrossRef
60. Specific nanomarkers fluorescence: in vitro analysis for EGFR overexpressed cells in triple-negative breast cancer and malignant glioblastoma
    Paula Vieira et al, 2022, Photodiagnosis and Photodynamic Therapy CrossRef
61. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study
    Adam Hermawan et al, 2022, Sci Rep CrossRef
62. Brain Tumor Characterization Using Radiogenomics in Artificial Intelligence Framework
    Biswajit Jena et al, 2022, Cancers CrossRef
63. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors
    Jing Wang et al, 2022, Chem. Pharm. Bull. CrossRef
64. Neuro-Oncology in Women
    Lauren Singer et al, 2023, Neurologic Clinics CrossRef
65. null
    Sarath S. Joseph et al, 2023 CrossRef
66. Interaction of a Novel Alternatively Spliced Variant of HSD11B1L with Parkin Enhances the Carcinogenesis Potential of Glioblastoma: Peiminine Interferes with This Interaction
    Ru-Huei Fu et al, 2023, Cells CrossRef
67. BRD4: New Hope in the Battle Against Glioblastoma
    Weichen Duan et al, 2023, Pharmacological Research CrossRef
68. null
    Ahmad Daher et al, 2023 CrossRef
69. null
    Josep Puig et al, 2023 CrossRef
70. Rare T263P epidermal growth factor receptor extracellular domain mutation of advanced non‐small cell lung cancer in a Vietnamese male patient
    Kien Hung Do et al, 2023, Respirology Case Reports CrossRef
71. Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach
    Amir Barzegar Behrooz et al, 2023, Cancers CrossRef
72. null
    Harsh Aahra et al, 2023 CrossRef
73. Adult IDH Wild-Type Glioblastoma Ultrastructural Investigation Suggests a Possible Correlation between Morphological Biomarkers and Ki-67 Index
    Pietro Familiari et al, 2023, Biomedicines CrossRef
74. Co-occurrence of glioma and multiple sclerosis: Prevailing theories and emerging therapies
    Enoch Kim et al, 2023, Multiple Sclerosis and Related Disorders CrossRef
75. Bioactive compounds from Actinidia arguta fruit as a new strategy to fight glioblastoma
    Catarina Macedo et al, 2023, Food Research International CrossRef
76. Anticancer effect of covalent purine-containing EGFR TKI, ZZC4 and its mechanism of action through network pharmacology
    Mawusse K.I. Attiogbe et al, 2023, Life Sciences CrossRef
77. Progress in Glioma Stem Cell Research.
    Vanajothi Ramar et al, 2023, Cancers (Basel) CrossRef
78. null
    Nadia M. Hamdy et al, 2024 CrossRef
79. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
    Davide Frumento et al, 2024, IJMS CrossRef
80. Live Organoid Cyclic Imaging
    David E. Reynolds et al, 2024, Advanced Science CrossRef
81. RBM24 Suppresses the Tumorigenesis of Glioblastoma by Stabilizing LATS1 mRNA
    Xuewen Lu et al, 2024, Biochem Genet CrossRef
82. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
    Andrea Álvarez-Vázquez et al, 2024 CrossRef
83. A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges
    Ardalan Pasdaran et al, 2024, Drug Development Research CrossRef
84. Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway
    Seunghee Bae et al, 2024, CMAR CrossRef
85. CircZNF609 and circNFIX as possible regulators of glioblastoma pathogenesis via miR-145-5p/EGFR axis
    Elham Ghadami et al, 2024, Sci Rep CrossRef
86. NFBTA: A Potent Cytotoxic Agent against Glioblastoma
    Hasan Turkez et al, 2019, Molecules CrossRef
87. Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression
    Elvis Martinez-Jaramillo et al, 2024, Cancers CrossRef
88. Analysis of IDH and EGFR as Biomarkers in Glioblastoma Multiforme: A Case-Control Study.
    Sohaib M. Al-khatib et al, 2024, Heliyon CrossRef
89. Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches
    Souhrid Sarkar et al, 2024, Human Cell CrossRef
90. In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development
    John Figg et al, 2024 CrossRef
91. Function of a complex of p‐Y42 RhoA GTPase and pyruvate kinase M2 in EGF signaling pathway in glioma cells
    Yoon‐Beom Lee et al, 2024, Journal of Neurochemistry CrossRef
92. null
    Sachin Kumar et al, 2024 CrossRef
93. Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review)
    Nilgun Cini et al, 2024, Oncol Rep CrossRef
94. Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration
    William Han Bae et al, 2024, Front. Oncol. CrossRef
95. Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma
    Allison R. Valerius et al, 2024, IJMS CrossRef
96. null
    , 2025 CrossRef
97. Exosomes as Nanocarrier for Neurotherapy: Journey from Application to Challenges
    Yogita Ale et al, 2024, Journal of Drug Delivery Science and Technology CrossRef
98. Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma
    Maria A. Jacome et al, 2024, Cancers CrossRef
99. null
    Inesa Navasardyan et al, 2025 CrossRef
100. Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma
     Agnieszka Rusak et al, 2024, Pharmacol. Rep CrossRef
101. Revolutionizing Cancer Detection: Harnessing Quantum Dots and Graphene-Based Nanobiosensors for Lung and Breast Cancer Diagnosis
     Soheil Sadr et al, 2025, BioNanoSci. CrossRef
102. Epidermal Growth Factor Receptors Unveiled: A Comprehensive Survey on Mutations, Clinical Insights of Global Inhibitors, and Emergence of Heterocyclic Derivatives as EGFR Inhibitors
     Manojmouli C et al, 2025, Journal of Drug Targeting CrossRef